Trial reportJournal of clinical oncology : official journal of the American Society of Clinical Oncology2019
Randomized Placebo Controlled Trial of Low-Dose Tamoxifen to Prevent Local and Contralateral Recurrence in Breast Intraepithelial Neoplasia.
Trial report in Journal of clinical oncology : official journal of the American Society of Clinical Oncology, 2019. The graph could read no effect estimate from its abstract, so it casts no vote on the map. It is linked to trial NCT04933240 (Tamoxifen Versus Estradiol in the Prevention of Unscheduled Bleeding in Etonogestrel Implant Users, a Randomized Controlled Pilot Trial), which is not on this map. Cited by 90 papers, 1 of them a synthesis that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Tamoxifen Versus Estradiol in the Prevention of Unscheduled Bleeding in Etonogestrel Implant Users, a Randomized Controlled Pilot Trial
Who cites it
90 citing papers in PubMed, 1 synthesis or guideline pooled it, 209 citations in OpenAlex.
- Management of Ductal Carcinoma In Situ: An Ontario Health (Cancer Care Ontario) Clinical Practice Guideline.Current oncology (Toronto, Ont.) · 2024Guideline
- Endoxifen for mammographic density reduction-results from the KARISMA endoxifen trial.Journal of the National Cancer Institute · 2026Trial
- Influence of endoxifen on mammographic density: results from the KARISMA-Tam trial.Journal of the National Cancer Institute · 2025Trial
- Preventative therapy for breast cancer: a clinical experience.Breast cancer research and treatment · 2023Trial
- Side effects of low-dose tamoxifen: results from a six-armed randomised controlled trial in healthy women.British journal of cancer · 2023Trial
- Patient and Provider Web-Based Decision Support for Breast Cancer Chemoprevention: A Randomized Controlled Trial.Cancer prevention research (Philadelphia, Pa.) · 2022Trial
- Time to Mammographic Density Decrease After Exposure to Tamoxifen.The oncologist · 2022Trial
- Low-Dose Tamoxifen for Mammographic Density Reduction: A Randomized Controlled Trial.Journal of clinical oncology : official journal of the American Society of Clinical Oncology · 2021Trial
- A Randomized Phase IIb Study of Low-dose Tamoxifen in Chest-irradiated Cancer Survivors at Risk for Breast Cancer.Clinical cancer research : an official journal of the American Association for Cancer Research · 2021Trial
- Randomized Phase IIB Trial of the Lignan Secoisolariciresinol Diglucoside in Premenopausal Women at Increased Risk for Development of Breast Cancer.Cancer prevention research (Philadelphia, Pa.) · 2020Trial
- Effect of Bazedoxifene and Conjugated Estrogen (Duavee) on Breast Cancer Risk Biomarkers in High-Risk Women: A Pilot Study.Cancer prevention research (Philadelphia, Pa.) · 2019Trial
- Randomised phase III trials of cancer prevention drugs: a systematic review and prediction of trial success.ESMO open · 2026Review
- Decoding the Genetic Hallmarks of Breast Cancer: Molecular Signatures, Prognostic and Therapeutic Perspectives.Applied biochemistry and biotechnology · 2026Review
- Effect of adjuvant endocrine therapy on recurrence and contralateral breast cancer in HR-positive DCIS after mastectomy.Breast (Edinburgh, Scotland) · 2026Observational
- Adherence to Endocrine Prevention in Patients with Atypical Hyperplasia and Lobular Carcinoma In Situ: Promising Trends from Real-World Use of Low-Dose Tamoxifen.Annals of surgical oncology · 2026Article
- Factors Associated with Low-Dose Tamoxifen Use among Women with Atypical Hyperplasia or Lobular or Ductal Carcinoma In Situ.Cancer prevention research (Philadelphia, Pa.) · 2026Article
- Evaluating the Implementation and Maintenance of a Breast Cancer Risk-Assessment and Prevention Program.Annals of surgical oncology · 2026Article
- Signaling pathways and targeted interventions for precancers.Signal transduction and targeted therapy · 2026Review
- Comparing Breast Cancer and Cardiovascular Risk among Women Undergoing Screening Mammography: Why Are Statins More Widely Accepted Compared with Chemoprevention?Cancer prevention research (Philadelphia, Pa.) · 2026Article
- Oestradiol and breast cancer prevention: a 40 year history and contemporary perspective.British journal of cancer · 2025Review
30 more citing papers are in PubMed but not listed here.
Corrections and comments
- Commented on by
Authors and funding
22 authors at 12 institutions in 2 countries.
Funding
No grant is acknowledged in the PubMed record.
Abstract
purposeTamoxifen administered for 5 years at 20 mg/d is effective in breast cancer treatment and prevention, but toxicity has limited its broad use. Biomarker trials showed that 5 mg/d is not inferior to 20 mg/d in decreasing breast cancer proliferation. We hypothesized that a lower dose given for a shorter period could be as effective in preventing recurrence from breast intraepithelial neoplasia but have a lower toxicity than the standard dose. PATIENTS AND
methodsWe conducted a multicenter randomized trial of tamoxifen, 5 mg/d or placebo administered for 3 years after surgery in women with hormone-sensitive or unknown breast intraepithelial neoplasia, including atypical ductal hyperplasia and lobular or ductal carcinoma in situ. The primary end point was the incidence of invasive breast cancer or ductal carcinoma in situ.
resultsFive hundred women 75 years of age or younger were included. After a median follow-up of 5.1 years (interquartile range, 3.9-6.3 years), there were 14 neoplastic events with tamoxifen and 28 with placebo (11.6
conclusionTamoxifen at 5 mg/d for 3 years can halve the recurrence of breast intraepithelial neoplasia with a limited toxicity, which provides a new treatment option in these disorders.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.